Hoppa till innehållet

OMXSPI+1,18%

S&P 500+0,09%

FTSE 100+0,05%

DAX+0,35%

NIKKEI+0,73%
BioInvent International AB: BioStock: BioInvent deepens collaboration with MSD

BioInvent has signed a new clinical collaboration and supply agreement with MSD. The agreement covers the evaluation of BioInvent's anti-TNFR2 antibody BI-1910 in combination with MSD's Keytruda in the second part of a phase I/IIa study in solid tumours. The monotherapy part of the study has been ongoing since December, and the first results are expected by year-end 2024.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/04/bioinvent-deepens-collaboration-with-msd/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Source:Cision
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill du bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1180kr
Prenumerera